[Skip to Content]

MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) launches third annual campaign promoting medicine side effects reporting

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched the third annual social media campaign to promote the importance of reporting suspected side effects from medicines to the Yellow Card Scheme. Taking place from 19-23 November, the campaign forms part of an awareness week involving 32 medicines regulators in the EU, Latin America, Australasia

Report suspected side effects to help make medicines safer

The Medicines and Healthcare products Regulatory Agency (MHRA) is running a social media campaign between 7-11 November to promote reporting of suspected side effects, as part of an EU-wide awareness week. Medicines have the potential to harm as well as cure. While they are usually safe and effective, side effects can happen. It is important

A new Yellow Card app: report on the go

All adverse incidents related to medical devices, including performance concerns for diagnostics, defective medicines (those that are not of an acceptable quality) and also counterfeit products are now reportable online to the Yellow Card Scheme in addition to the traditional reporting of suspected adverse drug reactions (ADRs). Prompt reporting ultimately makes medicines and devices safer

French health regulator reviews use of Avastin to treat AMD

College Statement The RCOphth notes with interest the move by the French health regulator, French National Agency for Medicines and Health Products Safety (ANSM), in asking Roche to provide information on the safety and efficiency of the off-label use of bevacizumab (Avastin) to treat wet age-related macular degeneration (AMD). Ranibizumab (Lucentis), which is licensed as

Class 2 Medicines Recall (action within 48 hours): COSOPT Preservative-Free, 20mg/ml +5mg/ml, eye drops, solution, single-dose container – Merck Sharp & Dohme Limited (EL (14)A/02)

Merck Sharp & Dohme Limited COSOPT Preservative-Free, 20mg/ml +5mg/ml, eye drops, solution, single-dose container (Dorzolamide / Timolol) PL 00025/0698 Batch number Expiry Date Pack size First distributed MK13D002 30 April 2015 60 single dose containers 9 September 2013 MK13D004 30 April 2015 60 single dose containers 4 July 2013 Merck Sharp and Dohme is recalling